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Acute Coronary Syndrome
Limited Effect of G-CSF in Acute MI Patients
While animal models suggest that stem cell mobilization by granulocyte colony-stimulating factor (G-CSF) has a positive impact on cardiac regeneration after
acute myocardial infarction (MI), the findings in human trials have been inconsistent.
Zohlnhöfer and colleagues performed a meta-analysis of 10 trials that randomized
post-MI subjects to G-CSF and reported serial assessments of ejection fraction (EF).
While significant improvements in EF were observed in both G-CSF and placebo
groups, there was not any benefit with G-CSF. This meta-analysis does not support a
beneficial effect of G-CSF in post-MI patients. See pages 1429 and 1438.
See figure.
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Acute Coronary Syndrome
No Significant Change in LDL Levels During ACS
Conventional wisdom is that cholesterol levels measured during an acute coronarysyndrome (ACS) are falsely low. This wisdom is based on limited evidence. Pitt
and colleagues analyzed changes in lipid parameters in the first 4 days after admission
for ACS in over 500 subjects. Blood samples were taken at admission (fasting or
non-fasting sample) and onDays 2 and 4 (fasting samples) for the direct measurement
of serum lipid levels. There were some statistically significant changes, but these were
clinically irrelevant as they ranged from 1% to 4%. These findings suggest that
directly-measured serum low-density lipoprotein (LDL) cholesterol does not change to
a clinically significant extent during hospitalization for an ACS and can be used to
initiate lipid-lowering therapy of the proper intensity. See pages 1440 and 1446.
See figure.
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Coronary Artery Disease
Atorvastatin 80 mg Is Highly Effective in Patients With Kidney Disease
Concerns regarding efficacy and toxicity have limited the utilization of high dosestatin therapy in patients with chronic kidney disease (CKD).This subanalysis of
the TNT (Treating to New Targets) study investigated the effects of atorvastatin in
patients with and without pre-existing CKD, which was defined as an estimated
glomerular filtration rate (eGFR) 60 ml/min/1.73m2. Nearly one-third of the
9,000 subjects in theTNTstudyhadCKD; these patientswere 1.3 timesmore likely
to suffer amajor cardiovascular event. Comparedwith atorvastatin 10mg, atorvastatin
80mg reduced the relative risk of major cardiovascular events by 32% in patients with
CKD and 15% in patients with normal eGFR. Both doses of atorvastatin were well
tolerated in patients with CKD. These results suggest that aggressive lipid-lowering
with atorvastatin 80mg is both safe and effective in reducing cardiovascular events in a
high-risk population with CKD and coronary artery disease. See page 1448.
See figure.
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Heart Rhythm Disorders
Two LV Leads May Improve Cardiac
Remodeling Compared With Standard Biventricular Pacing
While biventricular pacing can augment left ventricular (LV) reverse remodeling, only
60%ofpatientswill benefitwith a10%decrease inLVend-systolic volume.Leclercq
and colleagues hypothesized that stimulating the LV at multiple sites might improve
ventricular resynchronization. They performed a randomized crossover study to com-
pare the safety and efficacy of triple-site (3-V) with 2 LV leads versus standard dual-site
(2-V) biventricular stimulation. A cardiac resynchronization therapy device connected
to 1 RV and 2 LV leads, inserted in 2 separate coronary sinus tributaries, was
successfully implanted in 34 patients. A significantly higher LV ejection fraction and
smaller LV end-systolic volume were found after 3 months of 3-V than 2-V pacing.
See pages 1455 and 1463. See figure.
Valvular Heart Disease
Improving Mortality for Valve Replacement in Patients With LF/LGAS
Levy and colleagues studied outcomes from200 consecutive patients with low-flow/
low-gradient aortic stenosis (LF/LGAS), which was defined as an aortic valve area1
cm2, ejection fraction 35%, and mean gradient 30 mm Hg. The perioperative
mortality rate has decreased from 20% in the early 1990s to a contemporary rate of
approximately 10%. Operative risk was higher in patients with no contractile reserve
during dobutamine infusion, those with multivessel coronary artery disease, and those
with lowermean gradients. The authors conclude that given the very poor prognosis of
unoperated LF/LGAS, aortic valve replacement is a reasonable choice formost patients
with LF/LGAS. See page 1466.
